Report
Debbie Wang
EUR 101.80 For Business Accounts Only

Edwards prepares for the future with strategic acquisitions of transcatheter mitral technologies.

Edwards Lifesciences finished off 2017 in strong fashion, and we expect to moderately raise our fair value estimate to reflect margin expansion from favorable product mix shifts and the lower-than-expected effective tax rate, as well as the time value of money. We remain confident in Edwards’ narrow economic moat as the firm prepares to launch its Sapien 3 Ultra delivery system in Europe and the U.S. this year, and in European regulatory approval for its Centera self-expanding TAVR product. The ...
Underlying
EDWARDS LIFESCIENCES CORP

Edwards Lifesciences is engaged in patient-focused medical for structural heart disease, as well as critical care and surgical monitoring. The company is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company is also engaged in hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Debbie Wang

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch